AZD5153 enhances the chemo-sensitivity of gemcitabine on pancreatic cancer cells in vitro and in vivo

Abstract Background Pancreatic cancer is a malignant disease with a poor prognosis. Gemcitabine (GEM), the first-line treatment drug, shows limited efficacy because of the notorious drug resistance of pancreatic cancer. Therefore, the development of sensitive drugs for pancreatic cancer is essential...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Haixin Zhu, Minmin Shen, Yiqian Zhu, Ruoqi Wang, Rong Dong, Yuyu Huang, Lulin Zhu, Ying Li, Youyou Yan, Jiang Lou, Bo Zhang, Nengming Lin, Biqin Tan
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2025-08-01
Saila:	Cancer Cell International
Gaiak:	AZD5153 Gemcitabine Pancreatic cancer ERK/mTOR signaling MUC2
Sarrera elektronikoa:	https://doi.org/10.1186/s12935-025-03952-2
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!